Italia markets closed
FTSE MIB
33.922,16 +40,66 (+0,12%) Dow Jones
37.986,40 +211,02 (+0,56%) Nasdaq
15.282,01 -319,49 (-2,05%) Nikkei 225
37.068,35 -1.011,35 (-2,66%) Petrolio
83,39 +0,66 (+0,80%) Bitcoin EUR
59.988,72 +467,77 (+0,79%)
Sun Pharmaceutical Industries Limited (SUNPHARMA.NS)
NSE - NSE Prezzo in tempo reale. Valuta in INR.
Aggiungi a watchlist
Alla chiusura: 03:29PM IST
| Chiusura precedente | 1.516,40 |
| Aperto | 1.505,00 |
| Denaro | 0,00 x 0 |
| Lettera | 0,00 x 0 |
| Min-Max giorno | 1.503,70 - 1.528,30 |
| Intervallo di 52 settimane | 922,45 - 1.638,85 |
| Volume | |
| Media Volume | 2.683.823 |
| Capitalizzazione | 3,654T |
| Beta (5 anni mensile) | 0,53 |
| Rapporto PE (ttm) | 40,99 |
| EPS (ttm) | 37,15 |
| Prossima data utili | 24 mag 2024 - 28 mag 2024 |
| Rendimento e dividendo (futuro) | 12,50 (0,82%) |
| Data ex dividendo | 09 feb 2024 |
| Stima target 1A | 829,22 |
GlobeNewswireNidlegy™ Phase III PIVOTAL trial meets the study’s primary objective demonstrating statistically significant and clinically meaningful improvement in Recurrence-Free Survival for patients with locally advanced fully resectable melanoma
Intratumoral Nidlegy™ followed by surgery significantly improved the Recurrence-Free Survival compared to surgery alone PIVOTAL (NCT02938299) is the first and so far only Phase III trial demonstrating statistically significant and clinically meaningful benefit of a neoadjuvant therapy in fully resectable locally advanced melanoma patients Nidlegy™ is the first immunocytokine product to show positive data in a Phase III randomized clinical trial The results will be presented at an upcoming intern
© 2024 Yahoo. Tutti i diritti riservati.